Radically Increasing the Clinical Value of the ECG

“…some of the most significant advances in electrocardiography since its inception, which has historically had a limited, if any, role in the evolution of cardiac dysfunction. In the past, our cardiovascular community was resigned to the fact that surface ECGs are poor indicators for cardiac dysfunction.”

JACC Editorial Commentary
MyoVista Clinical Study – August 2020

Corporate Profile

HeartSciences is a healthcare information technology company advancing the use of ECG/EKGs through the integration of artificial intelligence. HeartSciences' MyoVista Insights™ Platform is a cloud-native, vendor- and device-agnostic ECG management system designed to modernize ECG workflows and improve clinical efficiency and decision-making. The platform's AI-ECG marketplace is designed to deliver AI-ECG algorithms into clinical workflows across a health system's existing ECG equipment.

Price delayed by 15 minutes

Featured Presentation

Explore our latest investor presentation to gain insights into our financial performance, strategic initiatives, and growth prospects. This comprehensive overview provides key information to help investors understand our market positioning and future opportunities.

View Investor Presentation

Latest Press Releases

Sign up for emails alerts

Stay connected and get the latest company news delivered to your inbox.

HeartSciences

550 Reserve Street, Suite 360
Southlake, TX 76092 USA
Email: info@heartsciences.com
Tel: 737-414-9213

Stock Transfer Agent

Equiniti Trust Company, LLC (formerly AST)
Email: HelpAST@equiniti.com
Tel: 1-800-937-5449 (toll free) or 1-718-921-8124.
Website: https://equiniti.com/us/ast-access

Investor Relations

Integrous Communications
Mark Komonoski - Partner
Direct: 877-255-8483
investorrelations@heartsciences.com
www.integcom.us